Shopping Cart
- Remove All
- Your shopping cart is currently empty
DMHCA is a selective LXR agonist with anti-inflammatory activity, which induces ABCA1 expression and upregulates FASN and SREBP-1alpha gene expression.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $29 | In Stock |
Description | DMHCA is a selective LXR agonist with anti-inflammatory activity, which induces ABCA1 expression and upregulates FASN and SREBP-1alpha gene expression. |
In vitro | Treatment of diabetic CD34+ cells with 10 μM DMHCA restored cell membrane fluidity to non-diabetic baseline levels. DMHCA restored bone marrow-derived TNF-α and IL-3 levels to baseline and significantly reduced CCL-2 production in bone marrow supernatant and systemic circulation. In addition, DMHCA increased the number of circulating vascular progenitor cells (CACs) in the bone marrow and peripheral circulation and facilitated the migration of vascular repair cells into the peripheral circulation. [1] |
In vivo | DMHCA was able to restore cholesterol homeostasis in the diabetic retina by oral administration of 8 mg/kg/day for 6 months. In diabetic retina, DMHCA significantly increased the levels of endogenous LXR ligand, norethisterol and total oxidized sterols. [1] |
Molecular Weight | 401.63 |
Formula | C26H43NO2 |
Cas No. | 79066-03-8 |
Smiles | C[C@@]12[C@]([C@]3([C@@]([C@]4(C)C(=CC3)C[C@@H](O)CC4)(CC1)[H])[H])(CC[C@@]2([C@@H](CCC(N(C)C)=O)C)[H])[H] |
Relative Density. | 1.06 g/cm3 (Predicted) |
Storage | store at low temperature | store at -20°C | Shipping with blue ice. | ||||||||||||||||||||
Solubility Information | DMSO: 5 mg/mL (12.45 mM.), Sonication is recommended. | ||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.